Validation of a Model for the Complex of HIV-1 Reverse Transcriptase with Nonnucleoside Inhibitor TMC125
- 25 April 2003
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 125 (20) , 6016-6017
- https://doi.org/10.1021/ja034308c
Abstract
The structure for the complex of nonnucleoside inhibitor TMC125 and HIV-1 reverse transcriptase has been determined and validated through computation of resistance profiles using Monte Carlo/free-energy perturbation calculations. The good quantitative agreement between the computed and experimental anti-HIV activities for TMC125, nevirapine, and efavirenz with wild-type RT and four common mutants (L100I, K103N, Y181C, and Y188L) confirms the correctness of the predicted structure and provides insights into the improved potency of this novel NNRTI. The blue shading in the figure indicates basic residues.Keywords
This publication has 5 references indexed in Scilit:
- The High Cost of PovertyScience, 2002
- Prediction of Activity for Nonnucleoside Inhibitors with HIV-1 Reverse Transcriptase Based on Monte Carlo SimulationsJournal of Medicinal Chemistry, 2002
- Structural basis for the inhibitory efficacy of efavirenz (DMP‐266), MSC194 and PNU142721 towards the HIV‐1 RT K103N mutantEuropean Journal of Biochemistry, 2002
- Validation of a Model for the Complex of HIV-1 Reverse Transcriptase with Sustiva through Computation of Resistance ProfilesJournal of the American Chemical Society, 2000
- Complexes of HIV-1 Reverse Transcriptase with Inhibitors of the HEPT Series Reveal Conformational Changes Relevant to the Design of Potent Non-Nucleoside InhibitorsJournal of Medicinal Chemistry, 1996